ФИБРОЗ ПЕЧЕНИ ПРИ ХРОНИЧЕСКОМ ГЕПАТИТЕ С – ИДЕАЛЬНАЯ МОДЕЛЬ ДЛЯ ИЗУЧЕНИЯ ФИБРОЛИЗА ПОСЛЕ ЭЛИМИНАЦИИ HCV
Аннотация
Фиброз печени – это патологический процесс, при котором здоровая ткань печени замещается сое- динительной (фиброзной) тканью, в то время как фибролиз (фибролизис) является обратным развитием фиброза. Долгое время фиброз печени считался необратимым, но в последнее время раскрыты новые механизмы фиброгенеза и фибролиза, разработаны экспериментальные модели лечения фиброза. Тем не менее животные модели часто не отражают всю сложность фиброза печени у человека, поэтому большинство лекарственных средств, эффективных у животных, не демонстрируют антифиброзное действие у людей. Особый интерес для изучения механизмов фиброгенеза и фибролиза представляет печень пациентов с ХГС после элиминации HCV, когда устранена основная причина воспаления и фиброгенеза. Так как у одних пациентов при отсутствии HCV фиброз печени продолжает прогрессировать, а у других – регрессировать, это делает данную физиологическую модель уникальной для исследования механизмов фибролиза и разработки возможных направлений противофиброзной терапии.
Литература
Tsyrkunov VM, Prokopchik NI, Andreev VP, Kravchuk RI, Chernyak LK. Klinicheskaja morfologija pecheni: fibroz [Clinical morphology of the liver: fibrosis]. Gepatologija i gastrojenterologija [Hepatology and gastroenterology]. 2018;2(1):39-51. edn: UFKJRI. (Russian).
Pérez-Tamayo R. Cirrhosis of the liver: a reversible disease? Pathol Annu. 1979;14(Pt 2):183-213.
Okazaki I, Maruyama K. Collagenase activity in experimental hepatic fibrosis. Nature. 1974;252(5478):49-50. https://doi.org/10.1038/252049a0.
Herbst H, Schuppan D, Milani S. Fibrogenese und Fibrolyse in der Leber [Fibrogenesis and fibrolysis in the liver]. Verh Dtsch Ges Pathol. 1995;79:15-27. (German).
Sezd infektsionistov Respubliki Belarus s mezhdunarodnym uchastiem "Aktualnye voprosy infektsionnykh boleznej"; 2025 April 3-4; Minsk [Internet]. Available from: https://www.bsmu.by/meropriyatiya/sezd-infektsionistov-respubliki-belarus-s-mezhdunarodnym-uchastiem-aktualnye-voprosy-infektsionnykh-/ (Russian).
Zhdanov KV, Kozlov KV, Sukachev VS, Zakharenko SM, Karyakin SS, Saulevich AV, Lobzin DYu, Yaremenko MV, Ivanov KS, Lyashenko YuI, Karev VE, Zakharkiv YuF, Bulankov YuI. Jeliminacija HCV-infekcii: istorija s prodolzheniem [Elimination of HCV-infection: a story with continuation]. Zhurnal infektologii [Journal of infectology]. 2018;10(4):6-13. (Russian).
Tsyrkunov V, Andreev V, Kravchuk R, Kondratovich I. Ito stellate cells (hepatic stellate cells) in diagnosis of liver fibrosis. Gastroenterol Hepatol Open Access. 2019;10(4):213-219.
Tsyrkunov VM, Prokopchik NI, Andreev VP, Protsenko DD. Gepatologiya. Klinicheskaya morfologiya pecheni [Hepatology. Clinical morphology of the liver]. Tsyrkunov VM, editor. Moskva: Prakticheskaja medicina; 2025. 748 p. (Russian).
Weiskirchen R, Weiskirchen S, Tacke F. Organ and tissue fibrosis: Molecular signals, cellular mechanisms and translational implications. Mol Aspects Med. 2019;65:2-15. https://doi.org/10.1016/j.mam.2018.06.003.
Shan L, Wang F, Zhai D, Meng X, Liu J, Lv X. New Drugs for Hepatic Fibrosis. Front Pharmacol. 2022;13:874408. https://doi.org/10.3389/fphar.2022.874408.
Weiskirchen R, Tacke F. Cellular and molecular functions of hepatic stellate cells in inflammatory responses and liver immunology. Hepatobiliary Surg Nutr. 2014;3(6):344-63. https://doi.org/10.3978/j.issn.2304-3881.2014.11.03.
Higashi T, Friedman SL, Hoshida Y. Hepatic stellate cells as key target in liver fibrosis. Adv Drug Deliv Rev. 2017;121:27-42. https://doi.org/10.1016/j.addr.2017.05.007.
Kondratovich IA, Tsyrkunov VM, Andreev VP, Kravchuk RI. Kharakteristika fenotipov stellatnykh kletok pri khronicheskom gepatite C [Characteristics of phenotypes of stellate cells in chronic hepatitis C]. Zhurnal Grodnenskogo gosudarstvennogo medicinskogo universiteta [Journal of the Grodno State Medical University]. 2022;20(4):393-399. https://doi.org/10.25298/2221-8785-2022-20-4-393-399. https://www.elibrary.ru/abvuhv (Russian).
Friedman S, Rockey D, Montgomery B. Hepatic fibrosis 2006: Report of the Third AASLD Single Topic Conference. Hepatology. 2006;45(1):242-249. https://doi.org/10.1002/hep.21459.
Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology. 2008;134(6):1655-1669. https://doi.org/10.1053/j.gastro.2008.03.003.
Tsuchida T, Friedman SL. Mechanisms of hepatic stellate cell activation. Nat Rev Gastroenterol Hepatol. 2017;14(7):397-411. https://doi.org/10.1038/nrgastro.2017.38.
Perepelyuk M, Terajima M, Wang AY, Georges PC, Janmey PA, Yamauchi M, Wells RG. Hepatic stellate cells and portal fibroblasts are the major cellular sources of collagens and lysyl oxidases in normal liver and early after injury. Am J Physiol Gastrointest Liver Physiol. 2013;304(6):G605-14. https://doi.org/10.1152/ajpgi.00222.2012.
Lepreux S, Desmoulière A. Human liver myofibroblasts during development and diseases with a focus on portal (myo)fibroblasts. Front Physiol. 2015;6:173. https://doi.org/10.3389/fphys.2015.00173.
Kim J, Seki E. Hyaluronan in liver fibrosis: basic mechanisms, clinical implications, and therapeutic targets. Hepatol Commun. 2023;7(4):e0083. https://doi.org/10.1097/HC9.0000000000000083.
Pellicoro A, Ramachandran P, Iredale JP, Fallowfield JA. Liver fibrosis and repair: immune regulation of wound healing in a solid organ. Nat Rev Immunol. 2014;14(3):181-194. https://doi.org/10.1038/nri3623.
Chida T, Ohta K, Noritake H, Matsushita M, Murohisa G, Kageyama F, Sasada Y, Oyaizu T, Tsugiki M, Tamakoshi K, Nakajima T, Suda T, Kawata K. Lysyl oxidase-like 2 as a predictor of hepatocellular carcinoma in patients with hepatitis C virus after sustained virological response. Sci rep. 2024;14(1):10864. https://doi.org/10.1038/s41598-024-61366-y.
Barry-Hamilton V, Spangler R, Marshall D, McCauley S, Rodriguez HM, Oyasu M, Mikels A, Vaysberg M, Ghermazien H, Wai C, Garcia CA, Velayo AC, Jorgensen B, Biermann D, Tsai D, Green J, Zaffryar-Eilot S, Holzer A, Ogg S, Thai D, Neufeld G, Van Vlasselaer P, Smith V. Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment. Nat Med. 2010;16(9):1009-1017. https://doi.org/10.1038/nm.2208.
Kordes C, Sawitza I, Müller-Marbach A, Ale-Agha N, Keitel V, Klonowski-Stumpe H, Häussinger D. CD133+ hepatic stellate cells are progenitor cells. Biochem Biophys Res Commun. 2007;352(2):410-7. https://doi.org/10.1016/j.bbrc.2006.11.029.
Paku S, Schnur J, Nagy P, Thorgeirsson SS. Origin and structural evolution of the early proliferating oval cells in rat liver. Am J Pathol. 2001;158(4):1313-23. https://doi.org/10.1016/S0002-9440(10)64082-5.
Zhao H, Zhu H, Zhang Y, Ding Y, Feng R, Li J, Ma T, Huang C. Lymphocyte-Specific Protein Tyrosine Kinase Contributes to Spontaneous Regression of Liver Fibrosis may by Interacting with Suppressor of Cytokine Signaling 1. Inflammation. 2023;46(5):1653-1669. https://doi.org/10.1007/s10753-023-01831-4.
Pellicoro A, Ramachandran P, Iredale JP, Fallowfield JA. Liver fibrosis and repair: immune regulation of wound healing in a solid organ. Nat Rev Immunol. 2014;14(3):181-94. https://doi.org/10.1038/nri3623.
Gao B, Radaeva S. Natural killer and natural killer T cells in liver fibrosis. Biochim Biophys Acta. 2013;1832(7):1061-9. https://doi.org/10.1016/j.bbadis.2012.09.008.
Tacke F, Zimmermann HW. Macrophage heterogeneity in liver injury and fibrosis. J Hepatol. 2014;60(5):1090-6. https://doi.org/10.1016/j.jhep.2013.12.025.
Wang Z, Du K, Jin N, Tang B, Zhang W. Macrophage in liver Fibrosis: Identities and mechanisms. Int Immunopharmacol. 2023;120:110357. https://doi.org/10.1016/j.intimp.2023.110357.
Kmieć Z. Cooperation of liver cells in health and disease. Adv Anat Embryol Cell Biol. 2001;161:III-XIII, 1-151. https://doi.org/10.1007/978-3-642-56553-3.
Ma PF, Gao CC, Yi J, Zhao JL, Liang SQ, Zhao Y, Ye YC, Bai J, Zheng QJ, Dou KF, Han H, Qin HY. Cytotherapy with M1-polarized macrophages ameliorates liver fibrosis by modulating immune microenvironment in mice. J Hepatol. 2017;67(4):770-779. https://doi.org/10.1016/j.jhep.2017.05.022.
Karlmark KR, Weiskirchen R, Zimmermann HW, Gassler N, Ginhoux F, Weber C, Merad M, Luedde T, Trautwein C, Tacke F. Hepatic recruitment of the inflammatory Gr1+ monocyte subset upon liver injury promotes hepatic fibrosis. Hepatology. 2009;50(1):261-74. https://doi.org/10.1002/hep.22950.
Yang YM, Seki E. TNFα in liver fibrosis. Curr Pathobiol Rep. 2015;3(4):253-261. https://doi.org/10.1007/s40139-015-0093-z.
Zhang Z, Wang J, Li H, Niu Q, Tao Y, Zhao X, Zeng Z, Dong H. The role of the interleukin family in liver fibrosis. Front Immunol. 2025;16:1497095. https://doi.org/10.3389/fimmu.2025.1497095.
Wang Q, Usinger W, Nichols B, Gray J, Xu L, Seeley TW, Brenner M, Guo G, Zhang W, Oliver N, Lin A, Yeowell D. Cooperative interaction of CTGF and TGF-β in animal models of fibrotic disease. Fibrogenesis Tissue Repair. 2011;4(1):4. https://doi.org/10.1186/1755-1536-4-4.
Fabregat I, Caballero-Díaz D. Transforming Growth Factor-β-Induced Cell Plasticity in Liver Fibrosis and Hepatocarcinogenesis. Front Oncol. 2018;8:357. https://doi.org/10.3389/fonc.2018.00357.
Poulsen KL, Cajigas-Du Ross CK, Chaney JK, Nagy LE. Role of the chemokine system in liver fibrosis: a narrative review. Dig Med Res. 2022;5:30. https://doi.org/10.21037/dmr-21-87.
Chalin A, Lefevre B, Devisme C, Barget N, Amiot L, Samson M. Circulating levels of CXCL11 and CXCL12 are biomarkers of cirrhosis in patients with chronic hepatitis C infection. Cytokine. 2019;117:72-78. https://doi.org/10.1016/j.cyto.2019.02.006.
Zimmermann HW, Tacke F. Modification of chemokine pathways and immune cell infiltration as a novel therapeutic approach in liver inflammation and fibrosis. Inflamm Allergy Drug Targets. 2011;10(6):509-36. https://doi.org/10.2174/187152811798104890.
2.png)
